Search results for: 'medic fuels develop deceleration'

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products. These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal le...

This research service provides an in-depth analysis of the European refurbished medical imaging equipment market. It analyses the revenue potential, market dynamics, and trends across countries in Central and Eastern Europe and Western Europe as a combined European market. The revenue of the European refurbished medical imaging equipment market has...

16 Apr 2015  |  North America  |  Market Research

Big Data Opportunities in the US Medical Imaging Market

Assessing Market Opportunities for Big Data Management and Big Data Analytics in Medical Imaging

Infographics

×

Medical imaging data volumes will soon be approaching the petabyte range forcing providers to explore Big Data tools to help capture, manage, view, and analyze data. Leading medical imaging and non-healthcare IT vendors are investing in solutions as well as business strategies to support the healthcare industry as it progresses on the Big Data jour...

17 Jun 2021  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

Infographics

×

This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report ...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

The healthcare industry is undergoing a data revolution, and analytics is at the heart of it. This Frost Radar will reveal the strategies, technologies, and innovations that are shaping the industry and driving success. By understanding the current landscape, digital health readers can stay ahead of the curve, identify emerging trends, and make in...

This research service encompasses microbiome technology trends and emerging innovations across: Disease Management This research segment explores the emerging role of microbiome-based therapeutics across a wide range of diseases, especially in the context of gastro-intestinal health, while providing strategic insights across the highly dynamic com...